Your Messages Inbox (1) 
Your Unread Messages
See All
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol
Journal of Rheumatology, 09/14/09
Badesch DB et al. – This study reports longterm survival rates for patients with scleroderma-associated PAH treated with IV epoprostenol. Although comparisons to historical data should be made with caution, this study reports a better survival outcome than natural history data on patients with scleroderma-associated PAH.
Methods- One hundred two patients diagnosed with PAH in association with scleroderma who received epoprostenol
- 51 PAH patients from a subject population of 56 who received epoprostenol
- 46 patients from an initial population of 55 subjects on conventional therapy who received epoprostenol in the extension study
- Open-label epoprostenol
- Adverse events, survival, and dosing information collected
- Probabilities of survival during the first and second years for all subjects who received epoprostenol during the initial randomized controlled study or during the extension study were 0.71 and 0.52
- Measure remained constant at 0.48 during the third and fourth years
Related Articles
New finding could lead to cure of pulmonary arterial hypertension
Internet Source, 10/26/09 Relevance Score: 82%Inhibitory Effects of Simvastatin on Platelet-derived Growth Factor Signaling in Pulmonary Artery Smooth Muscle Cells from Patients with Idiopathic Pulmonary Arterial Hypertension
Journal of Cardiovascular Pharmacology, 10/12/09 Relevance Score: 81%Gilead Sciences Announces Plans for Phase IV Clinical Trial Evaluating First-Line Combination Therapy Versus Monotherapy in Pulmonary Arterial Hypertension
Gilead, 11/03/09 Relevance Score: 80%Sequence Variants in BMPR2 and Genes Involved in the Serotonin and Nitric Oxide Pathways in Idiopathic Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Relation to Clinical Parameters and Comparison with Left Heart Disease
Respiration, 10/20/09 Relevance Score: 80%Measures of Response in Clinical Trials of Systemic Sclerosis: The Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis (EPOSS)
Journal of Rheumatology, 10/15/09 Relevance Score: 80%Today in Autoimmune/Heritable...keeping you current
Receive free subspecialty "5-minute updates" via email
Serum Procalcitonin in Systemic Autoimmune Diseases—Where Are We Now
Seminars in Arthritis and Rheumatism, 02/09/10Recent insights in the epidemiology of autoimmune diseases: Improved prevalence estimates and understanding of clustering of diseases
Journal of Autoimmunity , 02/08/10Activation of AMP-activated protein kinase by adiponectin rescues salivary gland epithelial cells from spontaneous and interferon--induced apoptosis
Arthritis & Rheumatism, 02/08/10Today in Connective Tissue Dz...keeping you current
Receive free subspecialty "5-minute updates" via email
Mycophenolate mofetil for localized scleroderma
International Journal of Clinical Rheumatology, 02/09/10Diagnosis and Management of Pulmonary Hypertension in Systemic Sclerosis
Current Rheumatology Reports, 02/09/10Natural history and manifestations of the hypermobility type Ehlers-Danlos syndrome: A pilot study on 21 patients
American Journal of Medical Genetics, 02/09/10
Article Search
Sponsor
Sponsor